Company / Free Cash Flow
Celldex Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$213.7M
FY2025
5-year range
-$213.7M / -$62.2M
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
#144 of 150
Health Care
What the data says
Among 150 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 4% for free cash flow. Free Cash Flow has declined for 5 consecutive years, from -$42M in FY2020 to -$214M in FY2025.
Based on SEC 10-K filings.
-$214M in FY2025.
Declined from -$109M to -$214M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 150This company -$213.7M Sector average $782.1M
▼
-127.3% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 33.8% year-over-year.
- Ranks #144 out of 150 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$213.7M | -33.8% |
| FY2024 | -$159.7M | -46.4% |
| FY2023 | -$109.1M | -3.4% |
| FY2022 | -$105.6M | -69.8% |
| FY2021 | -$62.2M | -48.2% |
| FY2020 | -$42.0M | +11.0% |
| FY2019 | -$47.1M | +59.3% |
| FY2018 | -$115.8M | -13.8% |
| FY2017 | -$101.7M | +12.1% |
| FY2016 | -$115.8M | -11.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026